www.medhub.com.au Open in urlscan Pro
2606:4700:4400::ac40:95b3  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main content


Toggle navigation
 * Sign In




Close
 * Events


POPULAR SEARCH

 * patients
 * patient
 * 1
 * mayzent
 * sma


RECENT NEWS

Multi-Disciplinary Consensus: A practical guide to changing the course of heart
failure and improving patient outcomes
What's their risk of Heart Failure?
Privacy and Safety Statement
Search
 1. EAS Congress 2023 | Posters


EAS CONGRESS 2023 | POSTERS




EAS CONGRESS 2023 | POSTERS

View Novartis-sponsored poster presentations from the EAS Congress 2023.

The content of this page is provided for the purpose of medical education only,
and may include information on unregistered products or off-label topics. Please
review the Australian Product Information before prescribing, available at
www.tga.gov.au.

Current LDL-C management in Germany – The VICTORION-IMPLEMENT study

AU-23864

Click here to view >

A real-world assessment of lipid-lowering therapy in patients with
atherosclerotic cardiovascular disease and hypercholesterolemia: A retrospective
database analysis in Germany

AU-23864

Click here to view >

Lipid-lowering treatment of patients with statin intolerance – Interim analysis
of an observational, prospective, multicenter registry

AU-23864

Click here to view >

Rationale and design of implement for Life study: A validation study of a
national lipid lowering strategy after acute coronary syndrome

AU-23864

Click here to view >

Consensus panel about implementation of guidelines on lipid-lowering management
after acute coronary syndrome and up to one year follow-up

AU-23864

Click here to view >

A study designed to determine the status of attitudes and behaviors of
physicians towards atherosclerosis and dyslipidemia in different clinics across
Turkey

AU-23864

Click here to view >

▼ LEQVIO (inclisiran) is subject to additional monitoring in Australia. This
will allow quick identification of new safety information. Healthcare
professionals are asked to report any suspected adverse events at
www.tga.gov.au/reporting-problems

For LEQVIO (inclisiran) prescribing information, please click here.

PBS Information: This product is not listed on the PBS.

This content is intended for Australian healthcare professionals and is is
non-promotional in intent, content and nature.

LEQVIO® and the LEQVIO® logo are registered trademarks of Novartis AG.

AU-24274, July 2023
Share Twitter Linkedin Facebook Pinterest
Print
Welcome to Novartis

This website is only intended for healthcare professionals with prescribing
authority

You are now leaving the medhub.com.au website. This link will take you to a
website to which our Privacy Policy does not apply and which may not comply with
the Australian regulatory requirements. Novartis is not responsible for your
interactions with that website. Further information relevant to the Australian
environment is available from Novartis Medical Information.
I am a Doctor

and agree to the privacy and cookie policy of this website

Cancel

Welcome to Novartis

This website is only intended for healthcare professionals with prescribing
authority

You are now leaving the medhub.com.au website. This link will take you to a
website to which our Privacy Policy does not apply and which may not comply with
the Australian regulatory requirements. Novartis is not responsible for your
interactions with that website. Further information relevant to the Australian
environment is available from Novartis Medical Information.
I am a Doctor

and agree to the privacy and cookie policy of this website

Cancel

Toolbox

Medical Information Service

Medical Enquiries, Information
services, Adverse Events and Product
Complaints please contact:

1800 671 203
medinfo.phauno@novartis.com
Colleagues are available from 9:00 to
17:00 from Monday to Friday
Toolbox Collapse


NOVARTIS AUSTRALIA

 * Terms of Use
 * Medical Information
 * Call Medical Information
 * Privacy Policy
 * Contact Us
 * About Cookies


SUBSCRIBE TO NOVARTIS

 * --------------------------------------------------------------------------------

Site directory
©2023 Novartis
This site is intended for local audiences.

NOVARTIS PHARMACEUTICALS AUSTRALIA PTY LIMITED ABN 18 004 244 160. 54 WATERLOO
ROAD, MACQUARIE PARK NSW 2113. PH (02) 9805 3555.   

✓
Thanks for sharing!
AddToAny
More…

Back to top


previousnextstart slideshow